Contextualizing the Price of Biosimilar Adalimumab Based on Historical Rebates for the Original Formulation of Branded Adalimumab

This cross-sectional study compares recent list and net prices for Humira after rebates with announced prices of interchangeable biosimilar Humira formulations.

Detalles Bibliográficos
Autores principales: Dickson, Sean R., Gabriel, Nico, Hernandez, Inmaculada
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10346129/
https://www.ncbi.nlm.nih.gov/pubmed/37440233
http://dx.doi.org/10.1001/jamanetworkopen.2023.23398

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10346129/
https://www.ncbi.nlm.nih.gov/pubmed/37440233
http://dx.doi.org/10.1001/jamanetworkopen.2023.23398

Ejemplares similares